Phase 2 Extensive-stage Small-cell Lung Cancer trials recruiting now

All Extensive-stage Small-cell Lung Cancer trials, every phase

Other phases for Extensive-stage Small-cell Lung Cancer

Phase 2 Extensive-stage Small-cell Lung Cancer trials

• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
  NCT06437509 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
  NCT07654400 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 58 locations
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
  NCT07459634 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
  NCT06223711 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
  NCT05068232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
  NCT05903092 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
  NCT06497530 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
  NCT06217757 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  NCT07061535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
  NCT05588388 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 3 locations
• Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
  NCT06536868 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 6 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.